Reaction
Sars-Cov-2 Test Negative reporting signals
As of the last recalculation, Sars-Cov-2 Test Negative appears in 675 FAERS reports alongside 26 co-occurring drug terms. The strongest observed disproportionality signal is MESNA INJECTION (PRR 158.6).
Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.
| Drug | Co-reports | PRR | ROR |
|---|---|---|---|
| Mesna Injection | 40 | 158.6 | 159.4 |
| Mesna | 40 | 155.7 | 156.4 |
| Trimethoprim | 32 | 87.8 | 88.1 |
| Certolizumab Pegol | 176 | 62.3 | 62.4 |
| Ifosfamide | 35 | 52.9 | 53.0 |
| Nirmatrelvir And Ritonavir | 73 | 46.5 | 46.6 |
| Docusate Sodium 100Mg | 34 | 46.1 | 46.2 |
| Cetirizine Hydrochloride Allergy | 40 | 43.2 | 43.3 |
| Cetirizine Hydrochloride Tablets | 40 | 43.2 | 43.3 |
| Piperacillin Sodium,Tazobactam Sodium | 35 | 42.9 | 42.9 |
| Doxorubicin Hydrochloride | 42 | 42.2 | 42.3 |
| Pseudoephedrine Hydrochloride | 13 | 39.8 | 39.8 |
| Pseudoephedrine Hcl | 13 | 37.1 | 37.1 |
| Meropenem | 29 | 29.1 | 29.1 |
| Benralizumab | 15 | 23.6 | 23.6 |
| Fosaprepitant Dimeglumine | 9 | 20.4 | 20.5 |
| Vincristine Sulfate | 18 | 19.4 | 19.4 |
| Venetoclax | 34 | 17.9 | 17.9 |
| Olaparib | 11 | 16.5 | 16.5 |
| Doxorubicin | 43 | 15.8 | 15.8 |
| Osimertinib | 14 | 13.7 | 13.7 |
| Budesonide, Glycopyrrolate, And Formoterol Fumarate | 4 | 11.9 | 11.9 |
| Ravulizumab | 5 | 11.5 | 11.5 |
| Acalabrutinib | 4 | 10.2 | 10.2 |
| Durvalumab | 6 | 9.2 | 9.2 |
| Bimekizumab | 6 | 8.8 | 8.8 |